Full Text
PCN5 COST-UTILITY ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC)- A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE

Abstract

Authors

R Brown A Benedict RE Mansel

Back to Volume 7, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×